134 related articles for article (PubMed ID: 10963376)
1. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features.
Horie S; Endo K; Kawasaki H; Terada T
Virchows Arch; 2000 Jul; 437(1):25-30. PubMed ID: 10963376
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
[TBL] [Abstract][Full Text] [Related]
3. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
[TBL] [Abstract][Full Text] [Related]
4. [Result of p53, ki-67 protein expression in cholangiocarcinoma with in situ hybridization and immunohistochemistry methods].
Wang X; Zhang J; Chen J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Feb; 22(1):57-60. PubMed ID: 12903495
[TBL] [Abstract][Full Text] [Related]
5. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma.
Momoi H; Itoh T; Nozaki Y; Arima Y; Okabe H; Satoh S; Toda Y; Sakai E; Nakagawara K; Flemming P; Yamamoto M; Shimahara Y; Yamaoka Y; Fukumoto M
J Hepatol; 2001 Aug; 35(2):235-44. PubMed ID: 11580146
[TBL] [Abstract][Full Text] [Related]
6. Differential cell cycle-regulatory protein expression in biliary tract adenocarcinoma: correlation with anatomic site, pathologic variables, and clinical outcome.
Jarnagin WR; Klimstra DS; Hezel M; Gonen M; Fong Y; Roggin K; Cymes K; DeMatteo RP; D'Angelica M; Blumgart LH; Singh B
J Clin Oncol; 2006 Mar; 24(7):1152-60. PubMed ID: 16505435
[TBL] [Abstract][Full Text] [Related]
7. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
8. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
[TBL] [Abstract][Full Text] [Related]
9. Comparative clinicopathological study of resected intrahepatic cholangiocarcinoma in northeast Thailand and Japan.
Suzuki H; Isaji S; Pairojkul C; Uttaravichien T
J Hepatobiliary Pancreat Surg; 2000; 7(2):206-11. PubMed ID: 10982615
[TBL] [Abstract][Full Text] [Related]
10. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
11. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between genetic alterations and clinicopathological features in intrahepatic cholangiocarcinoma].
Cong W; Finkelstein SD; Wu M
Zhonghua Bing Li Xue Za Zhi; 2001 Jun; 30(3):183-7. PubMed ID: 11866974
[TBL] [Abstract][Full Text] [Related]
14. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-191 acts as a tumor promoter by modulating the TET1-p53 pathway in intrahepatic cholangiocarcinoma.
Li H; Zhou ZQ; Yang ZR; Tong DN; Guan J; Shi BJ; Nie J; Ding XT; Li B; Zhou GW; Zhang ZY
Hepatology; 2017 Jul; 66(1):136-151. PubMed ID: 28194813
[TBL] [Abstract][Full Text] [Related]
16. p53 Mutations in human cholangiocarcinoma: a review.
Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD
Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419
[TBL] [Abstract][Full Text] [Related]
17. Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.
Tsokos CG; Krings G; Yilmaz F; Ferrell LD; Gill RM
Hum Pathol; 2016 Nov; 57():61-67. PubMed ID: 27396933
[TBL] [Abstract][Full Text] [Related]
18. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
19. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
20. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
